Ortho-biologics company launches cellular bone allograft

Eric Oliver -   Print  |

Ortho-biologics company Royal Biologics launched Magnus, a DMSO-free viable cellular bone allograft, the first of its kind to be DMSO-free.

Magnus uses viable spine-derived cells from the vertebral region and preserves them with a DMSO-free cryoprotectant. DMSO has been linked to post-transplant complications. Surgeons can use Magnus in bone graft-based procedures.

Researchers studied the Magnus Viable Allograft's performance in 75 consecutive TLIF fusions. The procedure had a 96 percent fusion rate, with 75 patients undergoing a total of 85 levels fused at 12 months, according to a study published in the International Journal of Spine Surgery.

More articles on practice management:
Dr. Bryan Little appointed to state medical board, task force
Former Medtronic, Bioventus executive becomes CEO at BlueWind Medical
Exactech co-founders retire, current CEO to transition to board role — 4 insights

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers